SEARCH

SEARCH BY CITATION

References

  • Albuisson J., Pecheux C., Carel JC, Lacombe D., Leheup B., Lapuzina P., Bouchard P., Legius E., Matthijs G., Wasniewska M., Delpech M., Young J., Hardelin JP, Dodé C.. Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1(KAL2). Hum Mutat. 2005;25: 9899.
  • Badano JL, Katsanis N.. Beyond Mendel: an evolving view of human genetic disease transmission. Nat Rev Genet. 2002;3: 779789.
  • Cariboni A., Pimpinelli F., Colamarino S., Zaninetti R., Piccolella M., Rumio C., Piva F., Rugarli EI, Maggi R.. The product of X-linked Kallmann's syndrome gene (KAL1) affects the migratory activity of gonadotropin-releasing hormone (GnRH)-producing neurons. Hum Mol Genet. 2004;13: 27812791.
  • Carlton VE, Harris BZ, Puffenberger EG, Batta AK, Knisely AS, Robinson DL, Strauss KA, Shneider BL, Lim WA, Salen G., Morton DH, Bull LN. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet. 2003;34: 9196.
  • Dodé C., Hardelin JP. Kallmann syndrome: fibroblast growth factor signaling insufficiency? J Mol Med. 2004;82: 725734.
  • Dodé C., Levilliers J., Dupont JM, de Paepe A., le Du N., Soussi-Yanicostas N., Coimbra RS, Delmaghani S., Compain-Nouaille S., Baverel F., Pêcheux C., le Tessier D., Cruaud C., Delpech M., Speleman F., Vermeulen S., Amalfitano A., Bachelot Y., Bouchard P., Cabrol S., Carel JC, de Waal H Delemarre-Van, Goulet-Salmon B., Kottler ML, Richard O., Sanchez-Franco F., Saura R., Young J., Petit C., Hardelin JP. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet. 2003;3: 463465.
  • Dodé C., Teixeira L., Levilliers J., Fouveaut C., Bouchard P., Kottler ML, Lespinasse J., Lienhardt-Roussie A., Mathieu M., Moerman A., Morgan G., Murat A., Toublanc JE, Wolczynski S., Delpech M., Petit C., Young J., Hardelin JP. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet. 2006;2: 16481652.
  • Franco B., Guioli S., Pragliola A., Incerti B., Bardoni B., Tonlorenzi R., Carrozzo R., Maestrini E., Pieretti M., Taillon-Miller P., Brown CJ, Willard HF, Lawrence CH, Persico MG, Camerino G., Ballabio A.. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature. 1991;353: 529536.
  • Gao YQ, Danciger M., Ozgul RK, Gribanova Y., Jacobson S., Farber DB. Association of the Asn306ser variant of the SP4 transcription factor and an intronic variant in the beta-subunit of transducin with digenic disease. Mol Vis. 2007;13: 287292.
  • Gonzalez-Martinez D., Kim SH, Hu Y., Guimond S., Schofield J., Winyard P., Vannelli GB, Turnbull J., Bouloux PM. Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism. J Neurosci. 2004;24: 1038410392.
  • Hardelin JP, Levilliers J., Blanchard S., Carel JC, Leutenegger M., Pinard-Bertelletto JP, Bouloux P., Petit C.. Heterogeneity in the mutations responsible for × chromosome-linked Kallmann syndrome. Hum Mol Genet. 1993;2: 373377.
  • Hardelin JP, Levilliers J., Del Castillo I., Cohen-Salmon M., Legouis R., Blanchard S., Compain S., Bouloux P., Kirk J., Moraine C., Chaussain J-L, Weissenbach J., Petit C.. X chromosome-linked Kallmann syndrome: stop mutations validate the candidate gene. Proc Natl Acad Sci U S A. 1992;89: 81908194.
  • Hebert JM, Lin M., Partanen J., Rossant J., McConnell SK. FGF signaling through FGFR1 is required for olfactory bulb morphogenesis. Development. 2003;130: 11011111.
  • Legouis R., Hardelin JP, Levilliers J., Claverie JM, Compain S., Wunderle V., Millasseau P., le Paslier D., Cohen D., Caterina D., Bougueleret L., de Waal H Delemarre-Van, Lutfalla G., Weissenbach J., Petit CH. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell. 1991;67: 423435.
  • Lin DC, Bullock CM, Ehlert FJ, Chen JL, Tian H., Zhou QY. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem. 2002;277: 1927619280.
  • Matsumoto S., Yamazaki C., Masumoto KH, Nagano M., Naito M., Soga T., Hiyama H., Matsumoto M., Takasaki J., Kamohara M., Matsuo A., Ishii H., Kobori M., Katoh M., Matsushime H., Furuichi K., Shigeyoshi Y.. Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. Proc Natl Acad Sci U S A. 2006;103: 41404145.
  • Maya-Nuñez G., Cuevas-Covarrubias S., Zenteno JC, Ulloa-Aguirre A., Kofman-Alfaro S., Méndez JP. Contiguous gene syndrome due to deletion of the first three exons of the kallmann gene and complete deletion of the steroid sulphatase gene. Clin Endocrinol. 1998a;48: 713718.
  • Maya-Nuñez G., Zenteno JC, Ulloa-Aguirre A., Kofman-Alfaro S., Mendez JP. A recurrent missense mutation in the KAL gene in patients with X-linked Kallmann's syndrome. J Clin Endocrinol Metab. 1998b;83: 16501653.
  • Muntoni F., Bonne G., Goldfarb LG, Mercuri E., Piercy RJ, Burke M., Yaou RB, Richard P., Récan D., Shatunov A., Sewry CA, Brown SC. Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. Brain. 2006;129: 12601268.
  • Ng KL, Li JD, Cheng MY, Leslie FM, Lee AG, Zhou QY. Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling. Science. 2005;308: 19231927.
  • Oliveira LM, Seminara SB, Beranova M., Hayes FJ, Valkenburgh SB, Schipani E., Costa EM, Latronico AC, Crowley WF Jr, Vallejo M.. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab. 2001;86: 15321538.
  • Pitteloud N., Meysing A., Quinton R., Acierno JS Jr, Dwyer AA, Plummer L., Fliers E., Boepple P., Hayes F., Seminara S., Hughes VA, Ma J., Bouloux P., Mohammadi M., Crowley WF Jr. Mutations in fibroblast growth factor receptor 1cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol. 2006;254–255: 6069.
  • Pitteloud N., Quinton R., Pearce S., Raivio T., Acierno J., Dwyer A., Plummer L., Hughes V., Seminara S., Cheng YZ, Li WP, Maccoll G., Eliseenkova AV, Olsen SK, Ibrahimi OA, Hayes FJ, Boepple P., Hall JE, Bouloux P., Mohammadi M., Crowley W.. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest. 2007a;117: 457463.
  • Pitteloud N., Zhang C., Pignatelli D., Li JD, Raivio T., Cole LW, Plummer L., Jacobson-Dickman EE, Mellon PL, Zhou QY, Crowley WF Jr. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A. 2007b;104: 1744717452.
  • Robertson A., MacColl GS, Nash JA, Boehm MK, Perkins SJ, Bouloux PM. Molecular modelling and experimental studies of mutation and cell-adhesion sites in the fibronectin type III and whey acidic protein domains of human anosmin-1. Biochem J. 2001;357: 647659.
  • Rosen SW, Gann P., Rogol AD. Congenital anosmia: detection thresholds for seven odorant classes in hypogonadal and eugonadal patients. Ann Otol Rhinol Laryngol. 1979;88: 288292.
  • Sambrook J., Russell D.. Preparation and analysis of eukaryotic genomic DNA. In: Nolan C., ed. Molecular Cloning: A Laboratory Manual. New York, NY: Cold Spring Harbor Laboratory Press; 2001; 6.16.31.
  • Sato N., Katsumata N., Kagami M., Hasegawa T., Hori N., Kawakita S., Minowada S., Shimotsuka A., Shishiba Y., Yokozawa M., Yasuda T., Nagasaki K., Hasegawa D., Hasegawa Y., Tachibana K., Naiki Y., Horikawa R., Tanaka T., Ogata T.. Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18sporadic patients. J Clin Endocrinol Metab. 2004;89: 10791088.
  • Schwanzel-Fukuda M., Bick D., Pfaff DW. Luteinizing hormone-releasing hormone (LHRH)-expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Brain Res Mol Brain Res. 1989;6: 311326.
  • Söderlund D., Canto P., Mendez JP. Identification of three novel mutations in the KAL1 gene in patients with Kallmann syndrome. J Clin Endocrinol Metab. 2002;87: 25892592.
  • Tosch V., Rohde HM, Tronchère H., Zanoteli E., Monroy N., Kretz C., Dondaine N., Payrastre B., Mandel JL, Laporte J.. A novel PtdIns3P and PtdIns(3,5)P2 phosphatase with an inactivating variant in centronuclear myopathy. Hum Mol Genet. 2006;15: 30983106.
  • Tsai P-S, Gill JC. Mechanisms of disease: insights into X-linked and autosomal-dominant Kallmann syndrome. Nat Clin Pract Endocrinol Metab. 2006;3: 160171.